triflusal has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agulló, J; Bacskai, BJ; Borrelli, LA; Clarimón, J; Coma, M; Da Rocha-Souto, B; España, J; Garcia-Alloza, M; Gómez-Isla, T; Guardia-Laguarta, C; Hyman, BT; Lleó, A; Rodríguez, M; Sánchez, MB; Saura, CA; Scotton, TC; Serenó, L | 1 |
| Frautschy, SA | 1 |
2 other study(ies) available for triflusal and Cognition Disorders
| Article | Year |
|---|---|
Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Axons; Brain; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Cognition Disorders; Cytokines; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroglia; Plaque, Amyloid; Proto-Oncogene Proteins c-fos; Salicylates | 2010 |
Thinking outside the box about COX-1 in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Central Nervous System Agents; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Humans; Membrane Proteins; Mice; Salicylates | 2010 |